fourth-quart top-lin trifecta spring catalyst
baricitinib panel order impact
thursday februari market open report fourth quarter
full year financi result exhibit total revenu quarter
million beat estim million consensu million
jakafi net product revenu unit state million lower
estim million consensu million iclusig revenu
record million top estim million
consensu million quarter record million
baricitinib royalti sale europ bottom line net loss
quarter million greater estim million consensu
million dilut loss per share higher estim
consensu respect full year dilut loss greater
consensu estim respect note
discrep actual ep consensu estim primarili due
increas expens quarter due up-front consider mileston
expens relat compani collabor licens agreement variou
partner non-gaap basi compani report go forward net
incom million per share end quarter billion
cash cash equival complet varianc analysi expect
consensu actual result summar exhibit
versus-host diseas gvhd also expect continu progress number on-going
plan clinic studi told compani potenti market
distinct agent includ novel compound summar compani
clinic progress exhibit highlight key near-term catalyst
expect three catalyst spring dramat affect share
readout epacadostat melanoma potenti panel review
baricitinib rheumatoid arthriti readout jakafi acut graft-
return equiti ttm
base wilmington delawar major oncology-focus biotechnolog compani
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
key binari event share upcom top-lin readout phase trial expect
first half believ posit data lead substanti appreci share provid
critic vote confid epacadostat develop program whole phase studi
evalu epacadostat keytruda merck versu keytruda monotherapi frontlin metastat
melanoma peg probabl success first phase studi read
combo could boost valu whole epacadostat keytruda phase program compris
phase trial five major tumor type current project market share epacadostat keytruda
frontlin melanoma treatment durat month probabl success
expect top-lin data spring co-primari endpoint progression-fre surviv
potenti initi look overal surviv os co-primari endpoint also expect preliminari analys
top-lin data statu biomark includ statu tumor mutat burden
rna sequenc engin expect analys biomark correl
efficaci reveal throughout high correl biomark could identifi
subpopul hyper-respons epacadostat could lead modif data analysi protocol
phase epacadostat trial potenti increas chanc success studi
eight remain nine phase inhibitor studi open accru patient asid
frontlin melanoma trial discuss phase epacadostat program includ combin studi
evalu epacadostat keytruda first- second-lin bladder cancer frontlin nonsmall-cel lung cancer
nsclc express all-com frontlin renal cell carcinoma rcc frontlin squamou cell
carcinoma head neck scchn also collabor bristol-my squibb
outperform evalu epacadostat opdivo frontlin scchn frontlin nsclc guid manag
keytruda/opdivo combin trial activ run end ninth latest studi
announc run collabor astrazeneca azn examin inhibitor
imfinzi patient local advanc stage unresect nsclc adjuv set trial slate
begin enrol first half
manag anticip fda could call advisori committe discuss baricitinib new drug
applic nda rheumatoid arthriti ra prior expect nda decis second quarter
baricitinib approv europ februari receiv complet respons letter
fda april state addit data would need determin appropri dose two
propos dose mg mg daili well character certain safeti signal observ
across treatment group particular across phase ii phase studi imbal sever cardiac
event baricitinib arm versu placebo ratio elicit concern regard safeti high-risk
popul ra howev also note overal rate event across trial fell within rang
gener ra popul follow discuss fda partner
abl resubmit nda contain addit dose efficaci safeti data without need addit
clinic studi expect offici decis around second quarter panel call action
date expect issu discuss detail provid insight imbal cardiac
event may view rel treatment benefit provid baricitinib safeti profil
demonstr oral jak inhibitor class far continu believ long-term safeti key potenti
success baricitinib jak inhibitor class whole
pivot studi jakafi steroid-refractori acut gvhd read first half pivot phase ii
studi steroid-refractori acut gvhd expect read first half year pend posit
data seek acceler approv jakafi indic expect file later
compani begun phase trial steroid-refractori chronic gvhd enrol pivot phase
ii studi essenti thrombocythemia et estim top-lin data
respect
manag issu non- guidanc continu reflect consist top-lin growth
continu expens manag balanc execut current clinic studi invest pipelin
in-hous effort collabor program made chang model reflect
manag issu jakafi sale guidanc billion repres increas
midpoint compani also reiter long-term guidanc billion unit
state maintain estim billion slightli higher guidanc well above-
guidanc street-high estim billion peak jakafi sale jakafi came million
lower third quarter repres growth fourth quarter note
sequenti decreas due excess inventori build half week third quarter
account million manag comment end fourth quarter inventori back
within normal rang annual jakafi product sale believ pattern
continu augment beyond follow potenti label expans gvhd essenti
thrombocythemia note end fourth quarter patient take jakafi
increas date jakafi penetr elig myelofibrosi mf popul
polycythemia vera pv popul ampl room growth peak estim jakafi
penetr elig mf popul elig pv popul exhibit jakafi
remain approv therapi second-lin set indic potenti competitor
near medium term note januari celgen celg outperform obtain global right
fedratinib inhibitor registr mf clinic develop pv part acquisit impact
biomedicin howev view fedratinib threat jakafi believ ultim use salvag
jakafi failur detail fedratinib analysi posit rel jakafi pleas refer
note publish januari impact biomedicin acquisit celgen affect jakafi
compani guid sg million repres increas
midpoint increas sg expens estim million million near
midpoint guidanc
 cog expect come within rang billion
million respect maintain estim billion slightli lower cog estim
million million fit guidanc achiev lower estim jakafi cog
percent sale
benefit tax reform compani guid non- long-term effect tax rate fall
follow util net oper loss tax credit carry-forward model occur
begin
base chang estim non- ep ep estim loss
greater loss previou estim gain differ attribut higher oper
expens match guidanc referenc
maintain outperform rate fair valu estim share exhibit probability-
adjust net present valu npv model assign per share jakafi per share iclusig per share
baricitinib per share epacadostat per share pipelin per share net cash end
arriv fair valu assess
upcom catalyst includ phase epacadostat truda data melanoma first half
data jakafi phase ii pivot studi steroid-refractori acut gvhd first half baricitinib
advisori panel spring initi pivot trial jakafi essenti thrombocythemia epacadostat keytruda
nsclc rcc scchn bladder cancer itacitinib gvhd b-cell malign dose escal
data fgfr brd pim inhibitor pair biopsi data in-hous combo
risk includ lack success pipelin includ epacadostat unforeseen competit jakafi
failur delay baricitinib approv unit state
incom royalti iclusig eu epacadostat revenues- contract total expensescost product sg chang fair valu acquisition-rel conting expenses- total oper oper interest incom interest debt exchang expens senior note conversions- unreal loss long term invest loss repurchase/redempt conv senior subordin notes- total incom pre-tax comprehens gain/ loss accret redempt valu redeem conv prefer stock- provis incom net non- reconciliationmileston revenu new exist partners- up-front consider mileston relat partners- non-cash stock comp equiti awards- asset impair in-process chang fair valu conting consideration- amort acquir product rights- chang fair valu equiti investments- non-cash interest exp relat conv notes- expens relat senior note conversions- tax effect non-gaap adjustments- total non- adjustments- non- net income- non- ep diluted- ep weight averag share outstand weight averag share outstand sourc william blair estim compani reportsexhibit corporationincom statement dollar thousand except per
blair estimateswillam blair estimatesactualactualwb estimate actual vs estimate con estactu vs consactu q/q growthcurrentpreviouscurr vs previousy/i growthcurrentpreviouscurr vs previousy/i growthin thousand except per share datarevenuesjakafi net product expens oper net ep william blair estim factset compani reportsexhibit corporationvari analysi william blair
drugind statusnotessteroid-refractori acut gvhdpivot phase ii phase data expect chronic gvhdphase thrombocythemiapivot phase acut gvhdphase cell lung cancerphas i/ii combin osimertinib malignanciesphas i/ii evalu aml expans cohort combo azacitadinediffus larg b-cell lymphomaphas ii lymphomaphas ii zone lymphomaphas ii cell lymphomaphas ii cancerphas ii ii data neoplasm rearrangementphas ii brd advanc malignanciesphas i/ii pim advanc malignanciesphas i/ii myeloid leukemia small cell lung cancerphas i/ii dose-escalationalso evalu sickle-cel diseas carcinomaphas i/ii dose-escalationiniti develop expect focu hepatocellular carcinomaunresect metastat melanoma phase combin keytruda top-lin data renal bladder head neck cancer phase combin keytruda head neck cancer phase combin opdivo nsclc phase combin imfinzi tumor type phase ii expans cohort combin keytruda multipl tumor type phase ii expans cohort combin opdivo multipl tumor type phase ii expans cohort combin imfinzi tumor type phase idose-escal complet monotherapi expans arg solid tumor phase i/ii develop expect focu i/o chemo gitr solid tumor phase i/ii develop expect focu i/o tumor phase i/ii develop expect focu i/o axl/mer indstart clinic studi clinic studi clinic studi platform studysolid tumor phase i/ii keytruda combin itacitinib platform studysolid tumor phase i/ii itacitinib combin epacadostat non-oncologytop ruxolitinib dermat vitiligophas iirheumatoid arthritisapprov europ japan issu fdafda decis expect around dermatitisphas psoriat arthritislilli expect phase begin lupu erythematosusphas iicapmatinib c-met licens novarti non-smal cell lung cancer liver cancerphas ii egfr wild-typ neg nsclc patient c-met amplif mutationsourc compani reportscanc target therapiescanc immun therapiespartn exhibit corporationpipelin progressruxolitinib william blair
settingpreval incid probabl successlaunch dateindicationwb estimate current market sharewb modelpeak shareprice/yeartreat durationpeak salespeak global high-risk myelofibrosi includ primari myelofibrosi post-polycythemia vera myelofibrosi post-essenti thrombocythemia high risk polycythemia vera intoler inadequ respons acut chronic high risk hu intoler essenti thrombocythemia intoler inadequ respons hydroxyurea harbor william blair estim compani reportsexhibit corporationjakafi assumptionsdrugpeak salesstag developmentestim launch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair marketedapprov nov marketedapprov juli eu market tier phase present valu addit william blair estimatessum-of-part fair valu exhibit corporationfair valuenet year-end import disclosur
